Out of 3.615, 106 studies were considered, including 8.126 subjects treated with TRT and 7.310 patients allocated to placebo. No difference between TRT and placebo was observed when major adverse CV events were considered. Whereas the incidence of non-fatal arrhythmias and AF was increased in the only trial considering CV safety as the primary endpoint, this was not confirmed when all other studies were considered (MH-OR 1.61[0.84;3.08] and 1.44[0.46;4.46]). Similarly, no relationship between endogenous T levels and AF incidence was observed after the adjustment for confounders Available data confirm that TRT is safe and it is not related to an increased CV risk.
Keyphrases
- replacement therapy
- end stage renal disease
- phase iii
- newly diagnosed
- risk factors
- atrial fibrillation
- smoking cessation
- ejection fraction
- chronic kidney disease
- clinical trial
- prognostic factors
- peritoneal dialysis
- emergency department
- study protocol
- case control
- randomized controlled trial
- electronic health record
- open label